Not sure that I understand yuor point. My persepctive is that it's sad to see a former $20 stock work its way down into the penny stock class.
Don't think that new patents will move the trading range at this point. ECOR received 510(k) for gammacore on Sept 23 2018. 2+ years later, revenues are still peanuts and losses (though now greatly reduced, thanks to new competent management) continue. One can hope for better results in the future, but headache treatment is still a category for which drug treatment is the 1st, 2nd and 3rd default choice for treatment by clinicians. This fact seems to be the primary marketing hurdle for ECOR. We need to give the new management a chance to address this problem. 2+ years after approval, one cannot talk about "futures" and patents forever; results need to kick in at some point in order to move the stock price.
My opinion.
Market Data 
Markets 
AI
